Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + subcutaneous daratumumab versus lenalidomide + dexamethasone in frail untreated multiple myeloma
2018-003535-30Phase 3Active
- Sponsor
- CHU de Lille
- Start
- Feb 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in multiple myeloma (MM) comparing Lenalidomide + daratumumab subcutaneous with Lenalidomide + dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Feb 2019; status: active.
02
Drugs
daratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2018-003535-30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003535-30.